CHINET 2010 surveillance of antibiotic resistance in Enterobacter spp.in China

Zhongju CHEN,Ziyong SUN,Yingchun XU,Xiaojiang ZHANG,Yunsong YU,Qing YANG,Yuxing NI,Jingyong SUN,Yuanhong XU,Jilu SHEN,Zhaoxia ZHANG,Ping JI,Hong ZHANG,Wanhua LI,Lianhua WEI,Ling WU,Yunjian HU,Xiaoman AI,Bei JIA,Wenxiang HUANG,Bin SHAN,Yan DU,Fu WANG,Demei ZHU,Fupin HU,Chuanqing WANG,Jianchang XUE,Chao ZHUO,Danhong SU
DOI: https://doi.org/10.16718/j.1009-7708.2012.03.004
2012-01-01
Abstract:UDjecuve 10 investigate tne ctistriDution ana antibiotic resistance of clinical Enterobacter isolates. Methods A total of 1 961 clinical strains of Enterobacter spp. were collected from 14 hospitals during January 1 through December 31, 2010. Antimicrobial susceptibility testing was performed with Kirby-Bauer method or determination of minimum inhibitory concentration. The results were analyzed according to CLSI 2010 standards. Results The main source of isolates was sputum (n = 1 146, 58.4%) and urine (n = 229, 11.7%), blood (n = 108, 5.5%), and others (n = 478, 24.4%). The resistance rate of Enterobacter strains was the highest to ampicillin, cefazolin and cefoxitin (>93%), relatively higher to ceftazidime and cefotaxime (38.6% and 51.2%, respectively), and relatively lower to piperacillin-tazobactam, cefepime, cefoperazone-sulbactam, ertapenem, amikacin, or ciprofloxacin (generally <20%), and the lowest to imipenem and meropenem (5.2% and 4.8%, respectively). The resistance rate varied with hospitals and theclinical setting (inpatients or outpatients). Eight strains were identified as pan-drug resistant including resistance to carbapen-em antibiotics. Conclusions Antibiotic resistance in clinical Enterobacter isolates is serious in China. Every hospital should take effective control measures to curb the growth of resistant strains.
What problem does this paper attempt to address?